HPV testing for cervical cancer screening appears more cost-effective than Papanicolau cytology in Mexico

Cancer Causes and Control

Volumn 22, Issue 2, 2011, Pages 261-272

  Flores, Yvonne N ^a   Bishai, David M ^b   Lőrincz, Attila ^c   Shah, Keerti V ^b   Lazcano Ponce, Eduardo ^d   Hernández, Mauricio ^e   Granados García, Víctor ^a   Pérez, Ruth ^a   Salmerón, Jorge ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^e SECRETARÍA DE SALUD   (Mexico)

Author keywords

Cervical cancer; Cost effectiveness; HPV; Mexico; Screening

Indexed keywords

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER GRADING; CANCER SCREENING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HEALTH CARE COST; HEALTH CARE DELIVERY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEXICO; OUTCOME ASSESSMENT; PAPANICOLAOU TEST; PRIORITY JOURNAL; SELF EXAMINATION; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; WART VIRUS;

EID: 79951726361     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-010-9694-3     Document Type: Article

References (40)

1. EC Lazcano-Ponce S Moss R Alonso J Salmerón M Hernández 1999 Cervical cancer screening in developing countries: why is it ineffective? The case of Mexico Arch Med Res 30 3 240 250 1:STN:280:DyaK1Mzls1yrsA%3D%3D 10.1016/S0188-0128(99)00006-8 10427875 (Pubitemid 29352176)
2. LS Palacio-Mejía E Lazcano-Ponce B Allen-Leigh M Hernández-Avila 2009 Regional differences in breast and cervical cancer mortality in Mexico between 1979-2006 Salud Pub Mex 51 2 S208 S219
3. E Lazcano-Ponce LS Palacio-Mejia B Allen-Leigh, et al. 2008 Decreasing cervical cancer mortality in Mexico: effect of Papanicolaou coverage, birthrate, and the importance of diagnostic validity of cytology Cancer Epidemiol Biomarkers Prev 17 2808 2817 10.1158/1055-9965.EPI-07-2659 18843027
4. JM Walboomers MV Jacobs MM Manos, et al. 1999 Human papillomavirus is a necessary cause of invasive cancer worldwide J Pathol 189 12 19 1:STN:280:DyaK1Mzot1CjsQ%3D%3D 10.1002/(SICI)1096-9896(199909)189:1<12::AID- PATH431>3.0.CO;2-F 10451482 (Pubitemid 29406813)
5. AT Lorincz 2003 Screening for cervical cancer: new alternatives and research Salud Pub Mex 45 3 S376 S387
6. SS Wang ME Sherman A Hildesheim JV Lacey Jr S Devesa 2004 Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000 Cancer 100 5 1035 1044 10.1002/cncr.20064 14983500 (Pubitemid 38232621)
7. Almonte M, Murillo R, Sánchez GI, Jerónimo J, Salmerón J, Ferreccio C, Lazcano-Ponce E, Herrero R (2010) New paradigms and challenges in cervical cancer prevention and control in Latin America. Salud Pub Mex 52(6):544-559
8. IARC Working Group on the Evaluation of Cervical Cancer Screening Programmes 1986 Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies BMJ 293 659 664 10.1136/bmj.293.6548.659
9. P Sasieni J Cuzick E Farmery 1995 Accelerated decline in cervical cancer mortality in England and Wales Lancet 346 8989 1566 1567 1:STN:280: DyaK28%2FpsVKgtA%3D%3D 10.1016/S0140-6736(95)92099-4 7491080
10. R Murillo 2007 Cytology-based cervical cancer screening programmes in Latin America HPV Today 12 6
11. J Cuzick CJ Meijer JM Walboomers 1998 Screening for cervical cancer Lancet 351 1439 1440 1:STN:280:DyaK1c3lsVakuw%3D%3D 10.1016/S0140-6736(05)79490- 3 9593447
12. Cuzick J, Sasieni P, Davies P, et al. (1999) A systematic review of the role of human papillomavirus testing within a cervical screening program. Health Technol Assess 3(14): i-iv, 1-196
13. C Clavel M Masure JP Bory, et al. 2001 Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women Br J Cancer 84 12 1616 1623 1:STN:280:DC%2BD3MzjsVSgug%3D%3D 10.1054/bjoc.2001.1845 11401314 (Pubitemid 32612492)
14. M Schiffman R Herrero A Hildesheim, et al. 2000 HPV DNA testing in cervical cancer screening: Results from women in a high-risk province of Costa Rica JAMA 283 87 93 1:STN:280:DC%2BD3c%2Fps1WntA%3D%3D 10.1001/jama.283.1.87 10632285 (Pubitemid 30038388)
15. JS Mandelblatt WF Lawrence SM Womack, et al. 2002 Benefits and costs of using HPV testing to screen for cervical cancer JAMA 287 18 2372 2381 10.1001/jama.287.18.2372 11988058 (Pubitemid 34493200)
16. G Koliopoulos M Arbyn P Martin-Hirsch M Kyrgiou W Prendiville E Paraskevaidis 2007 Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies Gynecol Oncol 104 1 232 246 10.1016/j.ygyno.2006.08.053 17084886 (Pubitemid 46054137)
17. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J (2006) Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24(3): S3/78-89
18. TC Wright Jr M Schiffman D Solomon, et al. 2004 Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening Obstet Gynecol 103 2 304 309 10.1097/01.AOG.0000109426.82624.f8 14754700
19. JD Goldhaber-Fiebert NK Stout JA Salomon KM Kuntz SJ Goldie 2008 Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16, 18 vaccination J Natl Cancer Inst 100 5 308 320 10.1093/jnci/djn019 18314477 (Pubitemid 351480523)
20. JJ Kim TC Wright SJ Goldie 2005 Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy J Natl Cancer Inst 97 12 888 895 10.1093/jnci/dji162 15956650 (Pubitemid 41417940)
21. EL Franco V Tsu R Herrero, et al. 2008 Integration of human papillomavirus vaccination and cervical cancer screening in Latin America and the Caribbean Vaccine 26 11 L88 L95 10.1016/j.vaccine.2008.05.026 18945406
22. R Herrero C Ferreccio J Salmerón, et al. 2008 New approaches to cervical cancer screening in Latin America and the Caribbean Vaccine 26 11 L49 L58 10.1016/j.vaccine.2008.05.025 18945402
23. R Murillo M Almonte A Pereira, et al. 2008 Cervical cancer screening programs in Latin America and the Caribbean Vaccine 26 11 L37 L48 10.1016/j.vaccine.2008.06.013 18945401
24. Instituto Mexicano del Seguro Social. Información estadística en Salud. Total nacional enero a octubre del 2009. En: http://www.imss.gob.mx/dpm/dis/Tabla.aspx?Srv=M00-1&ID=SCES006-001- 001&OPC=opc03
25. Y Flores K Shah E Lazcano, et al. 2002 Design and methods of the evaluation of an HPV-based cervical cancer screening strategy in Mexico: the Morelos HPV study Salud Pub Mex 44 4 335 344 (Pubitemid 34951473)
26. Drummond MF, Stoddart GL, Torrance GW, Stoddart GL, O'Brien BJ, O'Brien B (1997) Methods for the economic evaluation of health care programmes, 2nd edn. Oxford University Press, Oxford, pp 55-102
27. Drummond M F, Brandt A, Luce B, Rovira J (1993) Standardizing methodologies for economic evaluation in health care. In: Practice, problems, and potential. Int. J. Technol. Assess. Health Care Winter 9(1):26-36
28. A Arredondo T Damián 1997 Costos económicos en la producción de los servicios de salud: del costo de los insumos al costo de manejo de caso Salud Publica Mex 39 117 124 1:STN:280:DyaK2szislegug%3D%3D 9254435 (Pubitemid 27267319)
29. S Tan F Rutten B Ineveld W Redekop 2009 Comparing methodologies for the cost estimation of hospital services Eur J Health Econ 10 39 45 1:STN:280:DC%2BD1M%2Fhtl2kuw%3D%3D 10.1007/s10198-008-0101-x 18340472
30. J Salmerón EC Lazcano AT Lorincz, et al. 2003 Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico Cancer Causes Control 14 505 512 10.1023/A:1024806707399 12948281 (Pubitemid 36999965)
31. M Schiffman SK Kjaer 2003 Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia J Natl Cancer Inst Monogr 31 14 19 12807940
32. Mandelblatt JS, Fryback DG, Weinstein MC, Russell LB, Gold MR, Hadorn DC (1996) Assessing the effectiveness of health interventions. In: Gold MR, Siegel JE, Russell LB, Weinstein MC (eds) Cost-effectiveness in health and medicine. Oxford University Press, New York, pp 135-175
33. RP Insinga EJ Dasbach EH Elbasha A Puig LM Reynales-Shigematsu 2007 Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation Vaccine 26 1 128 139 10.1016/j.vaccine.2007.10.056 18055075 (Pubitemid 350218187)
34. Lazcano-Ponce E, Lörincz AT, Salmerón J, Fernández I, Cruz A, Hernández P, Mejia I, Hernández-Avila M (2010) A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program. Cancer Causes Control 21(10): 1693-700. Epub 2010 Jul 9
35. L Barbee E Kobetz J Menard, et al. 2010 Assessing the acceptability of self-sampling for HPV among Haitian immigrant women: CBPR in action Cancer Causes Control 21 3 421 431 10.1007/s10552-009-9474-0 19943103
36. D Serwadda M Wawer K Shah, et al. 1999 Use of a hybrid capture assay of self-collected vaginal swabs in rural Uganda for detection of human papillomavirus J Infect Dis 180 1316 1319 1:STN:280:DyaK1MvgvVymtQ%3D%3D 10.1086/315026 10479163 (Pubitemid 30070219)
37. YL Qiao JW Sellors PS Eder, et al. 2008 A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China Lancet Oncol 9 10 910 911 10.1016/S1470- 2045(08)70210-9
38. I Dzuba E Yunes Díaz B Allen, et al. 2002 The acceptability of self-collected samples for HPV testing vs. the Pap test as alternatives in cervical cancer screening J Womens Health Gend Based Med 11 3 265 275 10.1089/152460902753668466 11988136 (Pubitemid 34467555)
39. Goldie SJ, Diaz M, Constenla D, Alvis N, Andrus JK, Kim SY (2008) Mathematical models of cervical cancer prevention in Latin America and the Caribbean.Vaccine 19;26 Suppl 11:L 59-72
40. C Gutiérrez-Delgado C Báez-Mendoza E González-Pier AP de la Rosa R Witlen 2008 Generalized cost-effectiveness of preventive interventions against cervical cancer in Mexican women: results of a Markov model from the public sector perspective Salud Pub Mex 50 2 107 118